Boston Scientific Corporation (NYSE:BSX) Shares Bought by Triasima Portfolio Management inc.

Triasima Portfolio Management inc. boosted its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 8.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,569 shares of the medical equipment provider's stock after buying an additional 3,559 shares during the period. Triasima Portfolio Management inc.'s holdings in Boston Scientific were worth $4,496,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Cable Hill Partners LLC increased its stake in Boston Scientific by 3.7% during the 1st quarter. Cable Hill Partners LLC now owns 6,441 shares of the medical equipment provider's stock worth $663,000 after buying an additional 232 shares in the last quarter. Segall Bryant & Hamill LLC purchased a new stake in Boston Scientific during the 1st quarter worth approximately $8,234,000. Victory Capital Management Inc. increased its stake in Boston Scientific by 57.4% during the 1st quarter. Victory Capital Management Inc. now owns 805,696 shares of the medical equipment provider's stock worth $81,279,000 after buying an additional 293,928 shares in the last quarter. Bridgewater Advisors Inc. purchased a new stake in Boston Scientific during the 1st quarter worth approximately $987,000. Finally, Kornitzer Capital Management Inc. KS grew its position in shares of Boston Scientific by 16.3% in the first quarter. Kornitzer Capital Management Inc. KS now owns 12,312 shares of the medical equipment provider's stock valued at $1,242,000 after purchasing an additional 1,725 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Stock Performance

Shares of BSX stock traded up $1.43 during mid-day trading on Thursday, hitting $104.62. 9,473,047 shares of the stock were exchanged, compared to its average volume of 6,757,003. The stock's fifty day simple moving average is $103.38 and its two-hundred day simple moving average is $100.79. The stock has a market capitalization of $154.78 billion, a price-to-earnings ratio of 76.37, a P/E/G ratio of 2.69 and a beta of 0.68. Boston Scientific Corporation has a 12-month low of $71.88 and a 12-month high of $107.53. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.88 and a current ratio of 1.45.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a return on equity of 18.67% and a net margin of 11.58%. The firm had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. During the same quarter last year, the company posted $0.56 earnings per share. The business's revenue was up 20.9% on a year-over-year basis. On average, analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analyst Ratings Changes

BSX has been the subject of a number of analyst reports. Citigroup restated a "buy" rating and issued a $125.00 price target (up from $119.00) on shares of Boston Scientific in a research report on Thursday, May 22nd. Barclays upped their price objective on Boston Scientific from $118.00 to $125.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Evercore ISI upped their price objective on Boston Scientific from $110.00 to $112.00 and gave the company an "outperform" rating in a report on Thursday, April 24th. Leerink Partnrs upgraded Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. Finally, Robert W. Baird upped their price target on Boston Scientific from $115.00 to $120.00 and gave the stock an "outperform" rating in a research note on Thursday, April 24th. Twenty-two research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $116.09.

Insider Activity

In related news, SVP Vance R. Brown sold 4,826 shares of the firm's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $95.09, for a total transaction of $458,904.34. Following the transaction, the senior vice president owned 36,193 shares of the company's stock, valued at $3,441,592.37. This trade represents a 11.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Joseph Michael Fitzgerald sold 56,372 shares of the firm's stock in a transaction dated Wednesday, June 4th. The shares were sold at an average price of $102.88, for a total transaction of $5,799,551.36. Following the completion of the sale, the executive vice president owned 178,342 shares of the company's stock, valued at approximately $18,347,824.96. The trade was a 24.02% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 461,970 shares of company stock valued at $47,755,193. Insiders own 0.50% of the company's stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.